Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Active:	No
Cancer Type:	Lymphoma Neuroblastoma Sarcoma	NCT ID:	NCT03458728
Trial Phases:	Phase I Phase II	Protocol IDs:	19176 (primary) NCI-2018-00809 2017-000383-15
Eligibility:	6 Months - 21 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Bayer Corporation
NCI Full Details:	http://clinicaltrials.gov/show/NCT03458728

Summary

This study is designed to investigate whether the use of copanlisib is safe, feasible and
beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or
refractory to standard therapy.

Treatment Sites in Georgia

Aflac Cancer and Blood Disorders Center of Children’s at Egleston
1405 Clifton Road NE
3rd Floor
Atlanta, GA 30322
404-785-0853
www.choa.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.